FAQs

  • HIV - stands for Human Immunodeficiency Virus. A virus that weakens a patient’s immune system over time.
  • HIV-1 - the most common type of HIV worldwide.
  • CD4+ T-cell -  a type of cell that helps fight infections. Called CD4+ because of a type of receptor on the surface of the cell
  • combination antiretroviral therapy -  the combination of medicines, or regimen, used to treat HIV infection
  • R5 HIV 1 This type of HIV uses the coreceptor CCR5 (R5 for short) as a coreceptor to blind to and infect human cells.
  • T Cell Count  measurement of the amount of T-cells found in a sample of blood. 
  • CCR5-tropic HIV-1 - the type of HIV-1 that uses the CCR5 coreceptor to attach to CD4+ T-cells.
  • CD4+ T-cell count - the number of CD4+ T-cells in every cubic millimeter of blood.
  • Coreceptor – on the surface of CD4+ T-cells; used by HIV, along with the CD4 receptor, to attach to CD4+ T-cells.
  • Tropism – refers to the type of coreceptor that HIV uses to attach to CD4+ T-cells.
  • Tropism test or tropism assay – test done to determine which type of coreceptor a patient’s HIV uses to attach to a CD4+ T-cell.
  • AIDS – stands for Acquired Immunodeficiency Syndrome. The most severe phase of HIV infection. People with AIDS have such badly damaged immune systems that they get an increasing number of severe illnesses, called opportunistic illnesses
  • Opportunistic infections - infections that occur more frequently and are more severe in individuals with weakened immune systems, including people with HIV

Answers to frequently asked questions

What is SELZENTRY?

SELZENTRY is a prescription HIV-1 (Human Immunodeficiency Virus type 1) medicine used with other antiretroviral medicines to treat CCR5-tropic HIV-1 infection in people 2 years of age and older weighing at least 22 lb (10 kg). HIV-1 is the virus that causes AIDS (Acquired Immune Deficiency Syndrome).

Use of SELZENTRY is not recommended in people with dual/mixed or CXCR4‑tropic HIV‑1.

The safety and effectiveness of SELZENTRY has not been established in children younger than 2 years of age.

How should I take SELZENTRY?

  • Take SELZENTRY exactly as your healthcare provider tells you.
  • Do not change your dose or stop taking SELZENTRY without first talking with your healthcare provider.
  • If you miss a dose of SELZENTRY, take it as soon as you remember. Do not take 2 doses at the same time. If you are not sure about your dosing, call your healthcare provider.
  • Stay under the care of a healthcare provider while taking SELZENTRY.
  • Swallow SELZENTRY tablets whole. Do not chew the tablets.
  • SELZENTRY may be taken with or without food.
  • For children aged 2 years and older and weighing at least 22 lb (10 kg), your healthcare provider will prescribe a dose of SELZENTRY based on your child’s body weight and other medicines they are taking.
  • Tell your healthcare provider if your child has trouble swallowing tablets. SELZENTRY comes as tablets or as a liquid (oral solution).
  • SELZENTRY oral solution should be given with the supplied press-in bottle adapter and oral dosing syringe. See the Instructions for Use that comes with SELZENTRY oral solution for information about the right way to take a dose.
  • Do not run out of SELZENTRY. The virus in your blood may increase and the virus in your blood may become harder to treat. When your supply starts to run low, get more from your healthcare provider or pharmacy.
  • If you take too much SELZENTRY, call your healthcare provider or go to the nearest hospital emergency room right away.

What are the possible side effects of SELZENTRY?

  • SELZENTRY can cause serious side effects including:
  • See “What is the most important information I should know about SELZENTRY?”
  • Serious skin rash and allergic reactions. Severe and potentially life-threatening skin reactions and allergic reactions have been reported in some patients taking SELZENTRY. If you develop a rash with any of the following symptoms, stop using SELZENTRY and contact your doctor right away:
    • fever
    • generally ill feeling
    • muscle aches
    • blisters or sores in your mouth
    • blisters or peeling of the skin
    • redness or swelling of the eyes
    • swelling of the mouth or face or lips
    • problems breathing
    • yellowing of the skin or whites of your eyes
    • dark or tea-colored urine
    • pain, aching, or tenderness on the right side below the ribs
    • loss of appetite
    • nausea/vomiting
  • Heart problems including heart attack.
  • Low blood pressure when standing up (postural hypotension) can cause dizziness or fainting. You should avoid driving or operating heavy machinery if you have dizziness while taking SELZENTRY.
  • Changes in your immune system (Immune Reconstitution Syndrome) can happen when you start taking HIV-1 medicines. Your immune system may get stronger and begin to fight infections that have been hidden in your body for a long time. Tell your healthcare provider right away if you develop new symptoms after you start taking SELZENTRY.
  • Possible chance of infection or cancer. SELZENTRY affects other immune system cells and therefore may possibly increase your chance for getting other infections or cancer.

The most common side effects of SELZENTRY in adults include colds and cold-like symptoms, cough, fever, rash, bloating and gas, indigestion, constipation, and dizziness.

The most common side effects of SELZENTRY in children include vomiting, abdominal pain, diarrhea, nausea, and dizziness.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects of SELZENTRY. For more information, ask your healthcare provider or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1‑800‑FDA‑1088.

How should I store SELZENTRY?

  • Store SELZENTRY tablets and oral solution at room temperature between 68°F to 77°F (20°C to 25°C).

        Keep SELZENTRY and all medicines out of the reach of children.

 

What are the ingredients in SELZENTRY?

Active ingredient: maraviroc

Inactive ingredients: 

Tablets: Dibasic calcium phosphate (anhydrous), magnesium stearate, microcrystalline cellulose, and sodium starch glycolate. Tablet film-coating contains: FD&C blue #2 aluminum lake, soya lecithin, polyethylene glycol (macrogol 3350), polyvinyl alcohol, talc, and titanium dioxide.

Oral Solution: Citric acid, purified water, sodium benzoate, sodium citrate dihydrate, strawberry flavoring (501440T), and sucralose.